Information on Psoriasis from the National Institute of Arthritis and Musculoskeletal and Skin Diseases
Psoriasis is a chronic (long-lasting) skin disease of scaling and inflammation that affects greater than 3 percent of the United States population, or more than 5 million adults. Although the disease occurs in all age groups, it primarily affects adults. It appears about equally in males and females. Psoriasis occurs when skin cells quickly rise from their origin below the surface of the skin and pile up on the surface before they have a chance to mature. Usually this movement (also called turnover) takes about a month, but in psoriasis it may occur in only a few days. In its typical form, psoriasis results in patches of thick, red (inflamed) skin covered with silvery scales....more from National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health.
Psoriasis Information at the University of Pittsburgh Medical Center
Psoriasis is a chronic, inflammatory skin disease. Knees, elbows, scalp, trunk, and nails are the most commonly affected areas. There are several types of psoriasis…More at UPMC.
Psoriasis - MayoClinic.com
MayoClinic.com on Psoriasis.
What does psoriasis look like, and what can worsen psoriasis?
Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body….more from MedlinePlus, U.S. National Library of Medicine, National Institutes of Health.
What is psoriatic arthritis, how is it related to psoriasis, and how is psoriatic arthritis treated?
Psoriatic arthritis is an arthritis that is often associated with psoriasis of the skin. Psoriasis is a common, chronic skin condition that causes red patches on the body. About 1 in 20 people with psoriasis will develop arthritis with the skin condition....more from MedlinePlus, U.S. National Library of Medicine and the National Institutes of Health.
Dermatologist, Dr. Bruce Thiers, discusses in detail psoriasis, the symptoms, what causes the skin condition, what it looks like and treatments to reduce the inflammation and skin irritation at Medical University of South Carolina Podcast Library.
Podcast: Topical treatments for chronic plaque psoriasis
One of the largest new Cochrane reviews covers research into topical treatments for chronic plaque psoriasis. Anne Mason from the University of York in England describes their findings. Listen at The Cochrane Collaboration.
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Topical treatments are appropriate for patients who are candidates for localized therapy but may not be practical as monotherapy for most patients who are candidates for systemic and/or phototherapy (Pariser et al., 2007), where traditional systemic treatments, including methotrexate, cyclosporine (CyA), narrowband (NB) and broadband ultraviolet light B (UVB), psoralen plus ultraviolet A (PUVA), oral retinoids, and the newer biologic agents are prescribed. See National Guideline Clearinghouse major recommendations.
Abstract: Psoriasis: epidemiology, clinical features, and quality of life.
Psoriasis is a common chronic, recurrent, immune mediated disease of the skin and joints. It can have a significant negative impact on the physical, emotional, and, psychosocial wellbeing of affected patients. Psoriasis is found worldwide but the prevalence varies among different ethnic groups. It has a strong genetic component but environmental factors such as infections can play an important role in the presentation of disease. Full text available free through PubMed.
Abstract: The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients.
It is well established that several inflammatory-type conditions, such as arthritis, diabetes, cardiovascular disease, and irritable bowel disease exist comorbidly and at an increased incidence in patients with psoriasis. Psoriasis and other associated diseases are thought to share common inflammatory pathways. Conditions such as these, with similar pathogenic mechanisms involving cytokine dysregulation, are referred to as immune-mediated inflammatory diseases (IMIDs). Considerable evidence for the genetic basis of comorbidities in psoriasis exists. Full text available free through PubMed.
Abstract: Psoriasis as the marker of underlying systemic disease.
Psoriasis is associated with comorbidities that include metabolic syndrome and increased cardiovascular risk. These conditions share etiologic features and health consequences that directly correlate with the severity of psoriatic disease. This disease, in both its skin and joint manifestations, may represent a relevant healthcare issue as an indicator of a broader, underlying disorder of systemic inflammation, and warrants more comprehensive study and multidisciplinary collaboration on its pathophysiology, epidemiology, and treatment in relation to its comorbid conditions. Full text available free through PubMed.
Abstract: Treatment recommendations for psoriatic arthritis.
OBJECTIVE: To develop comprehensive recommendations for the treatment of the various clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic review of the literature and from consensus opinion. METHODS: Formal literature reviews of treatment for the most significant discrete clinical manifestations of PsA (skin and nails, peripheral arthritis, axial disease, dactylitis and enthesitis) were performed and published by members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations were drafted for each of the clinical manifestations by rheumatologists, dermatologists and PsA patients based on the literature reviews and consensus opinion. Full text available free through PubMed.
Abstract: Ustekinumab in the therapy of chronic plaque psoriasis.
Psoriasis is a chronic inflammatory disorder characterized by T cell dysregulation and a chronic inflammatory infiltrate within the epidermis. Several cytokines play an important role in the pathogenesis of psoriasis, including interleukin-12 (IL-12) and IL-23. These cytokines act via induction of pro-inflammatory cytokines which promote chronic inflammation and auto-reactivity. Ustekinumab is a fully human monoclonal antibody against the common p40 subunit of IL-12 and IL-23. Full text available free through PubMed.
Abstract: New biologics for psoriasis and psoriatic arthritis.
The prevalence of psoriasis is estimated to be 2.2% in the United States, and 6-39% of patients with psoriasis also develop psoriatic arthritis. New advances have been made in developing treatment options. See Abstract at PubMed.
Abstract: 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis.
BACKGROUND: The 308-nm excimer laser is a recent development in the treatment of psoriasis vulgaris, palmoplantar psoriasis, and psoriasis of the scalp. The XeCl excimer emits a 308-nm wavelength beam of light that is monochromatic and coherent. These properties allow selectivity when used as phototherapy against a psoriatic lesion while sparing healthy surrounding tissue. See Abstract at PubMed.
Abstract: New developments in topical sequential therapy for psoriasis.
Topical agents for the treatment of psoriasis are indicated for patients whose affected area is less than 10% of their skin. However, for long-term use, their effectiveness can be limited. Topical sequential therapy involves the application of a class I corticosteroid and calcipotriene in three different phases: the clearance phase, the transition phase and the maintenance phase. Full text available free through PubMed.
Abstract: Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis.
Topical vitamin D modulators are among the most widely used medications for the treatment of psoriasis. Calcitriol, the naturally occurring active form of vitamin D3, has long been used for topical psoriasis therapy in Europe and other parts of the world and was recently approved in the United States. Calcitriol 3 microg/g ointment has been extensively evaluated for the treatment of chronic plaque-type psoriasis and has been shown to be effective, safe and well-tolerated in a number of short-term and long-term clinical trials. See Abstract at PubMed.
Abstract: Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Psoriasis is a chronic skin disease that affects millions of people throughout the world. Even though cutaneous signs and symptoms are the most common clinical manifestations, the nails can be involved in up to 50% of cases, and their involvement remains an important yet often overlooked aspect of the disease. There is a broad spectrum of nail dystrophies associated with psoriasis, ranging from the common pitting and loosening of the nail plate to the less frequent discoloration and splinter hemorrhages seen in the nail bed. See Abstract at PubMed.
Looking for a Top-Rated
Consumers' Guide to Top Doctors finds the Doctors Rated Best by other Doctors
To find out who the top doctors are around the country, nonprofit Consumers' CHECKBOOK surveyed roughly 340,000 physicians to tell us which specialists they would want to care for a loved one. The Top Doctors database contains the names of over 23,000 doctors who were mentioned most often. Find top-rated doctors in the fifty largest metropolitan areas, in over thirty-five specialties, and more.
Source: FDA/Renee Gordon, HHS
Consumers' Guide to Top Doctors finds the Doctors Rated Best by other Doctors in over 30 specialties.
database of 23,000 top-rated physicians by
Doctors database of 23,000 top-rated
(over 35 different fields included) Specialty
Source: The National Psoriasis Foundation
Psoriasis Awareness Month
Consumers' Guide to Hospitals
Which Hospital Should You Choose (or Avoid)?
What makes the Consumers' Guide to Hospitals so special?
We've got 30 million answers to that question. That's how many hospital records Consumers' CHECKBOOK sifted through to calculate risk-adjusted death rates and adverse-outcome rates, and that's just part of the data used to rate the hospitals. The organization also sent out more than 280,000 questionnaires to physicians in 53 major metropolitan areas in the United States, asking them to rate their local hospitals; checked ratings of the hospitals by surveyed consumers; checked which hospitals were providing recommended tests and procedures for patients with specified medical problems; and more."
AARP The Magazine
Source: The National Psoriasis Foundation
National Psoriasis Foundation message board